对于具有药理动力学知识的临床前研究人员的论点:关于酒精的评论
1Department of Psychology, Indiana University Indianapolis, 402 N. Blackford St. LD 126L Indianapolis, IN, 46202, USA.
Alcohol (Fayetteville, N.Y.)
|November 19, 2025
概括
了解乙醇的药理动力学对于临床前酒精研究至关重要. 测量血液中乙醇度 (BECs) 可以确保精确的酒精剂量和可靠的跨物种研究结果.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
- 毒理学 毒理学 毒理学
背景情况:
- 在临床前研究中,酒精消费量经常被测量.
- 当前的做法往往忽视了饮酒的药理学意义.
- 这可能导致不准确的剂量估计和误解结果.
研究的目的:
- 强调在临床前酒精研究中考虑乙醇的药理动力学的必要性.
- 在酒精研究中倡导准确的剂量确定.
- 提高临床前酒精发现的翻译有效性.
主要方法:
- 评论回顾了在临床前研究中测量酒精消费的当前做法.
- 它强调了药理学中剂量反应关系的重要性.
- 它建议测量血液中乙醇度 (BEC) 作为剂量评估的黄金标准.
主要成果:
- 许多研究报告酒精摄入量没有考虑其药理动力学影响.
- 这可能导致报告的BEC在生理上是不可能的或可以忽略不计的.
- 准确的剂量评估对于理解强度,疗效和跨物种转化至关重要.
结论:
- 研究人员必须在临床前酒精研究中优先考虑药理动力学因素.
- 测量BEC是评估酒精剂量的最可靠方法.
- 当BEC测量是不可行的,需要仔细分析相对于新陈代谢的摄入速度是必要的.
相关概念视频
Pharmacokinetics: Overview
8.7K
Pharmacokinetics is a scientific discipline that focuses on the journey of a drug within the body, encompassing four key stages: absorption, distribution, metabolism, and elimination. The first stage, absorption, involves the drug's transfer into the bloodstream. Several factors dictate the extent and speed of this process. For example, the liver often metabolizes oral drugs before they reach systemic circulation, leading to only partial absorption. In contrast, intravenous (IV)...
8.7K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
241
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
241
Pharmacokinetic Models: Overview
1.8K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.8K
Preclinical Development: Overview
5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
217
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
217
Dosage Regimens: Partial Pharmacokinetic Parameters
138
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
138


